Clinical Trial Update: Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction [Phase 1]

View source ↗

Summary

Phase 1 trial of belinostat in patients with solid tumors and lymphomas across varying hepatic dysfunction shows completed status with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphomas
• Neoplasms

Drugs mentioned

• Belinostat (belinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neoplasms, Lymphomas | Phase 1 | Status: COMPLETED | Results posted: 2019-03-26